98%
921
2 minutes
20
Purpose: This study aims to assess the biometric alterations contributing to myopia in children who have undergone treatment for retinopathy of prematurity (ROP) and compare these changes with those observed in full-term myopic children.
Methods: Children who had undergone ROP treatment were recruited and classified according to their treatment methods. An age-matched group of myopic patients with no history of ROP treatment was also included. Complete perinatal history was collected, and a comprehensive ophthalmic examination, including cycloplegic refraction, was conducted. The biometric data of children in each study group were gathered using the IOL Master and Pentacam.
Results: The study recruited 14 patients in the intravitreal bevacizumab (IVB) group, 17 patients in the laser-treated group, and 13 individuals in the control group. There was no significant difference between the two patient groups regarding gestational age, birth weight, and age. In the IVB group, 50% of patients were myopic, compared to 52.9% in the laser-treated group. The incidence of high myopia was significantly higher in the laser-treated group ( 0.001). In the non-myopic group, changes in refractive error were solely related to changes in axial length ( = 0.003). However, in the myopic group, changes in refractive error were significantly associated with changes in anterior chamber depth ( 0.001), lens thickness ( 0.001), and axial length ( = 0.018). Furthermore, myopic children in the ROP group had significantly shorter axial lengths, shallower anterior chambers, thicker lenses, and steeper corneas compared to the control group (all 0.001).
Conclusion: Eyes with a history of ROP treatment, whether myopic or non-myopic, should be considered distinct entities. In patients who have undergone ROP treatment and have not developed myopia, changes in refractive error are primarily influenced by alterations in axial length, rather than changes in the anterior segment. Furthermore, children with myopia and a history of treatment for ROP (either IVB or laser) exhibit different biometric changes compared to myopic children without a history of ROP treatment, further underscoring their unique characteristics.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12258068 | PMC |
http://dx.doi.org/10.18502/jovr.v20.14953 | DOI Listing |
Br J Ophthalmol
September 2025
Capital Medical University, Beijing, China
Background: Retinopathy of prematurity (ROP), an oxygen-induced retinopathy (OIR), triggers a series of vascular lesions and inflammatory responses and results in visual impairment or even blindness. Triptolide (TP) possesses many pharmacological properties, including immunosuppressive and anti-tumour effects. However, the effects of TP on ROP and its underlying mechanisms remain unclear.
View Article and Find Full Text PDFFront Pediatr
August 2025
Department of Nursing, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
Retinopathy of prematurity (ROP) is a retinal disease characterized by abnormal vascular proliferation, primarily associated with premature delivery and low birth weight. Advances in perinatal and neonatal care have increased survival rates but have also contributed to a rising incidence of ROP, necessitating regular ROP screening. However, the screening procedure, which involves an eyelid speculum and ophthalmoscope, frequently induces pain.
View Article and Find Full Text PDFClin Exp Ophthalmol
September 2025
Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, San Diego, California, USA.
Retinopathy of prematurity (ROP) remains a major cause of preventable blindness in premature infants worldwide, with increasing incidence due to advancements in neonatal care. Management of ROP has been revolutionised by anti-vascular endothelial growth factor (anti-VEGF) treatments. Pivotal clinical trials have demonstrated the efficacy of anti-VEGF in the management of Type 1 ROP, while investigation of safety and long-term effects is ongoing.
View Article and Find Full Text PDFBr J Ophthalmol
August 2025
Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, Delhi, India
Anti-vascular endothelial growth factor (anti-VEGF) agents have demonstrated efficacy and short-term safety in the treatment of retinopathy of prematurity (ROP), establishing them as the preferred option for zone I and zone II posterior disease. Despite their advantages, the effects of anti-VEGF agents are relatively temporary. Consequently, ROP may reactivate or recur if retinal vascularisation has not sufficiently progressed and significant areas of avascular anterior retina remain while the anti-VEGF agents are cleared from the vitreous cavity.
View Article and Find Full Text PDFMedicina (Kaunas)
July 2025
Department of Medicine, National heart and Lung Institute, Imperial College London, London SW7 2AZ, UK.
Neonatal respiratory distress syndrome (NRDS), resulting from a deficiency of pulmonary surfactant (PS), can cause alveoli to collapse. Glucocorticoids reduce inflammation and are effective in reducing pulmonary swelling. This study aims to assess the effectiveness of the combination of PS and budesonide in the management of NRDS.
View Article and Find Full Text PDF